|

| 产地 | 中国 |
| 品牌 | 爱必信(absin) |
| 货号 | abs810437 |
| 用途 | 见爱必信官网 |
| 英文名称 | 见爱必信官网 |
| 包装规格 | 5mg,5mg,5mg,5mg,10mg,10mg,10mg,10mg,50mg,50mg,50mg,50mg,100mg,100mg,100mg,100mg,1g,1g,1g,1g |
| 纯度 | >98%% |
| CAS编号 | 868540-17-4 |
| 别名 | 卡非佐米;PR171;PR 171;PR-171 |
| 分子式 | |
| 是否进口 | 否 |
|
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Carfilzomib (PR-171) 产品别名:见爱必信官网 英文别名:Carfilzomib (PR-171) 靶点:Proteasome CAS:868540-17-4 纯度:>98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM. 溶解性:DMSO : 47 mg/mL (65.3 mM) 体外研究:
Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. Carfilzomib directly inhibits osteoclasts formation and bone resorption. 体内研究:Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice.
产品信息订购:
|